SAA1 has also been proposed as a lung cancer biomarker, and patients with lung cancer who have higher levels of plasma SAA1 have less favorable outcomes (Kim et al., 2015; Milan et al., 2012; Sung et al., 2011). This evidence concerns the gene SAA1 and lung cancer.